Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:administered_as |
intravenous infusion
subcutaneous injection |
| gptkbp:administered_by |
gptkb:healthcare_professionals
hospital settings high-risk patients subcutaneous injection |
| gptkbp:approves |
gptkb:vaccine
|
| gptkbp:associated_with |
reduced mortality rates
|
| gptkbp:available_on |
a treatment option
|
| gptkbp:can_be_administered_with |
other vaccines
|
| gptkbp:can_be_combined_with |
other COVID-19 treatments
|
| gptkbp:can_be_used_in |
immunocompromised patients
|
| gptkbp:clinical_trial |
gptkb:Regeneron_Pharmaceuticals
Phase 3 |
| gptkbp:consists_of |
gptkb:casirivimab
gptkb:imdevimab |
| gptkbp:developed_by |
gptkb:Regeneron_Pharmaceuticals
|
| gptkbp:first_authorized_in |
November 2020
|
| https://www.w3.org/2000/01/rdf-schema#label |
REGEN-COV
|
| gptkbp:involves |
monoclonal antibody infusion
two monoclonal antibodies |
| gptkbp:is_a |
gptkb:vaccine
substitute for vaccination |
| gptkbp:is_administered_to_patients_who_are |
at high risk for severe disease
|
| gptkbp:is_administered_to_patients_with |
high-risk conditions
|
| gptkbp:is_available_in |
gptkb:various_countries
|
| gptkbp:is_considered |
a significant advancement in treatment options.
a therapeutic monoclonal antibody an important tool in managing COVID-19 |
| gptkbp:is_effective_against |
certain variants
all COVID-19 variants |
| gptkbp:is_evaluated_by |
ongoing studies
safety and efficacy variants of concern |
| gptkbp:is_part_of |
Regeneron's COVID-19 treatment portfolio
emergency response to COVID-19 therapeutic strategies for COVID-19 treatment guidelines for COVID-19 |
| gptkbp:is_recommended_by |
health authorities
|
| gptkbp:is_recommended_for |
post-exposure prophylaxis
|
| gptkbp:is_studied_in |
various clinical trials
prophylactic use |
| gptkbp:is_targeted_at |
gptkb:SARS-Co_V-2
|
| gptkbp:is_used_for |
COVID-19 patients
|
| gptkbp:is_used_in |
emergency situations
clinical practice |
| gptkbp:marketed_as |
gptkb:REGEN-COV
|
| gptkbp:mechanism_of_action |
neutralizing antibodies
|
| gptkbp:part_of |
COVID-19 response strategies
COVID-19 therapeutic options |
| gptkbp:received_emergency_use_authorization |
gptkb:FDA
|
| gptkbp:requires |
medical supervision
|
| gptkbp:shown_to_be_effective_in |
reducing viral load
|
| gptkbp:shown_to_prevent |
COVID-19 progression
|
| gptkbp:shown_to_reduce |
hospitalization rates
|
| gptkbp:side_effect |
infusion reactions
|
| gptkbp:suitable_for |
mild to moderate COVID-19 without risk factors
|
| gptkbp:used_for |
preventing severe COVID-19
|
| gptkbp:used_in |
outpatient settings
|
| gptkbp:bfsParent |
gptkb:Regeneron
|
| gptkbp:bfsLayer |
4
|